Evidence map›Paper›PMID 40997327›Full record

ArticleCancer discovery2025

Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes.

Yuning J Tang, Haiqing Xu, Nicholas W Hughes, Paloma Ruiz, Samuel H Kim, Emily G Shuldiner, Steven S Lopez, Jess D Hebert, Saswati Karmakar, Laura Andrejka and 13 more

Abstract read
In one paragraph

Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. A STAG2-PAXIP1/PAGR1 axis suppresses lung tumorigenesis.The Journal of experimental medicine · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Yuning J TangDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0009-0006-7037-2901
Haiqing XuDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-9124-3192
Nicholas W HughesDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-9004-6288
Paloma RuizDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-6208-5087
Samuel H KimCancer Biology Program, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-8353-6190
Emily G ShuldinerDepartment of Biology, Stanford University, Stanford, California.ORCID 0000-0002-5018-0500
Steven S LopezDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0009-0008-0926-0016
Jess D HebertDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-8778-5941
Saswati KarmakarDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-0315-5924
Laura AndrejkaDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-2202-5626
Deniz Nesli DolcenDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-2441-7313
Gabor BorossDepartment of Biology, Stanford University, Stanford, California.ORCID 0000-0002-7208-5678
Pauline ChuDepartment of Pathology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-6561-6453
Christian A KunderDepartment of Pathology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-1514-7550
Colin DetrickDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0009-0002-4115-1668
Sarah E PierceCancer Biology Program, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-9145-9559
Emily L AshkinCancer Biology Program, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-7363-7860
William J GreenleafDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-1409-3095
Anne K VossWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.ORCID 0000-0002-3853-9381
Tim ThomasWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.ORCID 0000-0002-7623-8344
Matt van de RijnDepartment of Pathology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-1909-9739
Dmitri A PetrovDepartment of Biology, Stanford University, Stanford, California.ORCID 0000-0002-3664-9130
Monte M WinslowDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-5730-9573

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI MICHAEL KENNEY · 2007 to 2026
$71.4M
Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1M
Unraveling mechanisms of tumor suppression in lung cancerR01CA234349 · NCI · STANFORD UNIVERSITY · PI PETROV, DMITRI, WINSLOW, MONTE MEIER · 2019 to 2023
$2.4M
Defining and perturbing gene regulatory dynamics in the developing human brainR01NS128028 · NINDS · STANFORD UNIVERSITY · PI William James Greenleaf · 2023 to 2026
$2.4M
Genetic dissection of oncogenic Kras signalingR01CA230025 · NCI · STANFORD UNIVERSITY · PI WINSLOW, MONTE MEIER · 2021 to 2025
$2.2M
Biological and cancer-associated role of epitranscriptomic gene expression regulationK00CA245784 · NCI · STANFORD UNIVERSITY · PI Deniz Nesli Dolcen · 2023 to 2026
$386k
Pancreatic cancer stem cells: PD2-mediated novel mechanistic link and metabolomic alterationsK00CA234962 · NCI · STANFORD UNIVERSITY · PI KARMAKAR, SASWATI · 2021 to 2024
$363k
Pancreatic cancer stem cells: PD2-mediated novel mechanistic link and metabolomic alterationsF99CA234962 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KARMAKAR, SASWATI · 2018 to 2019
$89k
Chromatin and immune regulation of tumor growth and progressionF99CA284289 · NCI · STANFORD UNIVERSITY · PI ASHKIN, EMILY LORIN · 2023 to 2023
$49k
National Cancer Institute (NCI) R01-CA230025NCI NIH HHS F99 CA234962NCI NIH HHS F99 CA284289NCI NIH HHS K00 CA234962NCI NIH HHS K00 CA245784NCI NIH HHS P30 CA124435NCI NIH HHS R01 CA230025NCI NIH HHS R01 CA234349NCI NIH HHS T32 CA009302NINDS NIH HHS R01 NS128028
6 · The paper itself

Abstract

Epigenomic dysregulation is widespread in cancer. However, the specific epigenomic regulators and the processes they control to drive cancer phenotypes are poorly understood. We used a novel high-throughput in vivo method to perform iterative functional screens of >250 epigenomic regulators within autochthonous oncogenic Kras-driven lung tumors. We identified many previously unappreciated epigenomic tumor suppressor and tumor dependency genes. We show that a specific HBO1 complex and MLL1 complex are robust tumor suppressors in lung adenocarcinoma. Histone modifications generated by the HBO1 complex are frequently reduced in human lung adenocarcinomas and are associated with worse clinical features. HBO1 and MLL1 complexes co-occupy shared genomic regions, affect chromatin accessibility, and control the expression of canonical tumor suppressor genes and lineage fidelity. The HBO1 complex is epistatic with the MLL1 complex and other tumor suppressor genes in lung adenocarcinoma development. Collectively, these results provide a phenotypic roadmap of epigenomic regulators in lung tumorigenesis in vivo. SIGNIFICANCE: Using a novel functional genomics method in vivo, we investigated epigenomic regulators in lung tumorigenesis. We discovered multiple novel genes that affect tumor growth. We show that the HBO1 and MLL1 complexes interact to suppress lung adenocarcinoma. Our findings provide broad insights into the epigenomic regulatory landscape of lung cancer.

Indexed as

Histone-Lysine N-MethyltransferaseLung NeoplasmsMyeloid-Lymphoid Leukemia ProteinAdenocarcinoma of LungAnimalsCell Line, TumorEpigenesis, GeneticEpigenomicsGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansMiceHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia Protein

Identifiers

PMID40997327
PMCPMC12469823

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.